Comparative in vitro activity of sparfloxacin (AT 4140, RP 64206--SPFX) against 275 multiresistant clinical isolates.
The in-vitro activity of sparfloxacin was compared with that of pefloxacin, ofloxacin, ciprofloxacin, imipenem, ceftazidime, gentamicin and amikacin against 275 multiresistant nosocomial clinical isolates. They consisted of Pseudomonas aeruginosa (37), Enterobacter cloacae (42), Acinetobacter anitratus (60), Klebsiella pneumoniae (37) and Staphylococcus sp (99). Minimum inhibitory concentrations (MIC90) and geometric mean MICs for sparfloxacin were as follows (mg/l): P. aeruginosa 128-23.7, E. cloacae 1-0.13, A. anitratus 2-0.14, K. pneumoniae 1-0.08, MRSA 16-0.98, MSSA 0.12-0.03, MRSE 0.25-0.12 and MSSE 0.12-0.05. It is concluded that sparfloxacin was the most potent agent against staphylococci and A. anitratus including strains resistant to the other quinolones while ciprofloxacin was the most potent agent against P. aeruginosa, E. cloacae and K. pneumoniae.
Giamarellou
H
H
Athens University School of Medicine, 1st Department of Propedeutic Medicine, Laiko General Hospital, Greece.
Voutsinas
D
D
Xirouchaki
E
E
D000583:Amikacin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000187:drug effects; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D007769:Lactams; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D015363:Quinolones / Q000494:pharmacology*; D013210:Staphylococcus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D007769:Lactams; D015363:Quinolones; D000583:Amikacin; C061363:sparfloxacin